ATE554775T1 - Phospholipid-zusammensetzungen und ihre verwendungen - Google Patents

Phospholipid-zusammensetzungen und ihre verwendungen

Info

Publication number
ATE554775T1
ATE554775T1 AT08852865T AT08852865T ATE554775T1 AT E554775 T1 ATE554775 T1 AT E554775T1 AT 08852865 T AT08852865 T AT 08852865T AT 08852865 T AT08852865 T AT 08852865T AT E554775 T1 ATE554775 T1 AT E554775T1
Authority
AT
Austria
Prior art keywords
lipids
lrh
administration
blood glucose
glucose levels
Prior art date
Application number
AT08852865T
Other languages
English (en)
Inventor
David Moore
Jae Lee
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE554775T1 publication Critical patent/ATE554775T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08852865T 2007-11-16 2008-11-17 Phospholipid-zusammensetzungen und ihre verwendungen ATE554775T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98850507P 2007-11-16 2007-11-16
PCT/US2008/012846 WO2009067182A2 (en) 2007-11-16 2008-11-17 Phospholipid compositions and uses thereof

Publications (1)

Publication Number Publication Date
ATE554775T1 true ATE554775T1 (de) 2012-05-15

Family

ID=40668049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08852865T ATE554775T1 (de) 2007-11-16 2008-11-17 Phospholipid-zusammensetzungen und ihre verwendungen

Country Status (7)

Country Link
US (1) US8410085B2 (de)
EP (1) EP2219652B1 (de)
AT (1) ATE554775T1 (de)
AU (1) AU2008326800A1 (de)
CA (1) CA2705530A1 (de)
DK (1) DK2219652T3 (de)
WO (1) WO2009067182A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0915523D0 (en) 2009-09-07 2009-10-07 Genome Res Ltd Cells and methods for obtaining them
US20130210143A1 (en) * 2010-05-20 2013-08-15 Fundacion Publica Andaluza Progreso Y Salud Novel methods for preventing or treating diabetes
US9512406B2 (en) 2013-12-20 2016-12-06 The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone Generating hepatocytes
CN113908158A (zh) 2016-02-22 2022-01-11 诺华股份有限公司 使用fxr激动剂的方法
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
WO2019244137A1 (en) * 2018-06-22 2019-12-26 Fonterra Co-Operative Group Limited Use of polar lipids to treat or prevent gestational diabetes mellitus
CN115364111B (zh) * 2021-05-17 2024-04-02 中国医学科学院基础医学研究所 甘油磷脂类化合物在治疗肿瘤中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
AU2738497A (en) * 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US6537806B1 (en) 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
GB0014437D0 (en) * 2000-06-14 2000-08-09 Porter William L Immune response stimulation
JP2006506403A (ja) 2002-10-25 2006-02-23 カーツ、シーモア、ジェイ． インスリン抵抗性、成人発症型糖尿病及び代謝性症候群ｘの治療法
WO2004108140A1 (en) * 2003-06-05 2004-12-16 Doosan Corporation Composition for inhibiting differentiation or growth of fat cells
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
MX2008007075A (es) 2005-12-02 2008-11-12 Mdrna Inc Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa.

Also Published As

Publication number Publication date
WO2009067182A3 (en) 2009-07-23
EP2219652B1 (de) 2012-04-25
DK2219652T3 (da) 2012-08-06
US8410085B2 (en) 2013-04-02
WO2009067182A2 (en) 2009-05-28
AU2008326800A1 (en) 2009-05-28
CA2705530A1 (en) 2009-05-28
EP2219652A4 (de) 2010-11-10
EP2219652A2 (de) 2010-08-25
US20100331281A1 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
ATE554775T1 (de) Phospholipid-zusammensetzungen und ihre verwendungen
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2010129138A3 (en) Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
WO2003082078A3 (en) Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
CY1117312T1 (el) Θεραπευτικη αγωγη συνουκλεϊνοπαθειων
WO2011014661A3 (en) Liver x receptor agonists
Cavalcanti et al. Administration of reconstituted polyphenol oil bodies efficiently suppresses dendritic cell inflammatory pathways and acute intestinal inflammation
EA201200939A1 (ru) Липиды, липидные композиции и способы их применения
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
TR201908522T4 (tr) Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
NO20092150L (no) Fremgangsmater for behandling av hyperkolesterolemi
JP2016517888A5 (de)
WO2010042886A3 (en) Pyrones for the treatment of metabolic disorders
EA202091999A3 (ru) Применение ингибиторов dpp iv
BRPI0922796A2 (pt) Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo
WO2009120919A3 (en) Fenofibrate dosage forms
IN2012MN02262A (de)
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA201190209A1 (ru) Соединения для лечения метаболических расстройств
EA201190208A1 (ru) Соединения для лечения метаболических расстройств
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2009074969A3 (en) Spingosine-1-phosphate, analogues and antagonists for use as medicaments
MX2015008837A (es) Composiciones parenterales estables de dnj.
Tanaka et al. Role of uremic toxins and oxidative stress in the development of chronic kidney disease–mineral and bone disorder